from Reuters: Health News https://ift.tt/2mubfGr
Saturday, 28 September 2019
Results of GSK and AstraZeneca trials may widen ovarian cancer drug use
GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.
from Reuters: Health News https://ift.tt/2mubfGr
from Reuters: Health News https://ift.tt/2mubfGr
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment